- Report
- March 2024
- 44 Pages
From €6721EUR$6,995USD£5,746GBP
- Clinical Trials
- July 2020
- 216 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Clinical Trials
- June 2020
- 433 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Clinical Trials
- May 2020
- 174 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Clinical Trials
- May 2020
- 172 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Report
- July 2023
- 93 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- July 2021
- 114 Pages
Global
From €3200EUR$3,568USD£2,832GBP
- Report
- December 2023
- 132 Pages
Global
From €913EUR$950USD£780GBP
- Report
- April 2019
- 187 Pages
Global
From €5160EUR$5,370USD£4,411GBP
- Report
- April 2023
- 147 Pages
Global
From €5764EUR$5,999USD£4,928GBP
- Report
- August 2021
- 187 Pages
Global
From €5926EUR$6,168USD£5,067GBP
- Book
- May 2021
- 224 Pages
- Book
- November 2018
- 464 Pages
- Book
- September 2013
- 152 Pages
Conjunctivitis, commonly known as pink eye, is an inflammation of the conjunctiva, the thin, transparent membrane that lines the inner surface of the eyelid and covers the white part of the eye. It is a common eye condition that can be caused by a variety of factors, including allergies, bacteria, viruses, and irritants. In the optical market, conjunctivitis is a major concern, as it can cause significant discomfort and can lead to vision loss if left untreated.
Treatment for conjunctivitis typically involves the use of eye drops or ointments, which can be prescribed by an optometrist or ophthalmologist. In addition, lifestyle changes such as avoiding allergens and wearing protective eyewear can help reduce the risk of developing conjunctivitis.
Companies in the conjunctivitis market include Allergan, Bausch + Lomb, Novartis, and Santen Pharmaceuticals. These companies produce a variety of eye drops and ointments to treat conjunctivitis, as well as other eye conditions. Show Less Read more